Sun Pharma’s UNLOXCYT gets NCCN Category 2A recommendation for locally advanced skin cancer

The updated recommendation adds to the drug’s existing Category 2A designation for metastatic cutaneous squamous cell carcinoma
This is a short summary. The full story is published by Indianpharmapost.
Read full story at Indianpharmapost
